Ever since the discovery of aspirin, small molecule therapeutics have been widely prescribed to treat inflammation and pain. Aspirin and several small molecule NSAIDs are known to inhibit the enzymes cyclooxygenase-1 (COX-1) and -2 (COX-2). Despite the success of NSAIDs to treat inflammatory disorders, the development of a clinically useful small molecule NSAIDs with decreased side effect profiles is an ongoing effort. The recent discovery and development of selective COX-2 inhibitors was a step toward this direction. Emerging trends are represented by the progress in the development of hybrid agents such as nitric oxide donor-NSAIDs (NO-NSAIDs) and dual COX/lipoxygenase (LOX) inhibitors. This review focuses on the recent advances in the rational design of small molecule NSAIDs in therapy.
References
[1]
Vane, J.R. The fight against rheumatism: From willow bark to COX-1 sparing drugs. J. Physiol. Pharmacol.？2000, 51, 573–586. 11192932
[2]
Marnett, L.J. The COXIB experience: A look in the rearview mirror. Annu. Rev. Pharmacol. Toxicol.？2009, 49, 265–290, doi:10.1146/annurev.pharmtox.011008.145638. 18851701
[3]
Inotai, A.; Hanko, B.; Meszaro, A. Trends in the non-steroidal anti-inflammatory drug market in six central-eastern european countries based on retail information. Pharmacoepidemiol. Drug Saf.？2010, 19, 183–190, doi:10.1002/pds.1893. 20014174
[4]
Meade, E.A.; Smith, W.L.; DeWitt, D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem.？1993, 268, 6610–6614. 8454631
Penning, T.D.; Talley, J.J.; Bertenshaw, S.R.; Carter, J.S.; Collins, P.W.; Docter, S.; Graneto, M.J.; Lee, L.F.; Malecha, J.W.; Miyashiro, J.M.; Rogers, R.S.; Rogier, D.J.; Yu, S.S.; Anderson, G.D.; Burton, E.G.; Cogburn, J.N.; Gregory, S.A.; Koboldt, C.M.; Perkins, W.E.; Seibert, K.; Veenhuizen, A.W.; Zhang, Y.Y.; Isakson, P.C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J. Med. Chem.？1997, 40, 1347–1365, doi:10.1021/jm960803q. 9135032
[8]
Prasit, P.; Wang, Z.; Brideau, C.; Chan, C.C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J.F.; Ford-Hutchinson, A.W.; Gauthier, J.Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Léger, S.; Mancini, J.; O'Neill, G.P.; Ouellet, M.; Percival, M.D.; Perrier, H.; Riendeau, D.; Rodger, I.; Zamboni, R. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg. Med. Chem. Lett.？1999, 9, 1773–1778. 10406640
[9]
Luong, C.; Miller, A.; Barnett, J.; Chow, J.; Ramesha, C.; Browner, M.F. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat. Struct. Biol.？1996, 3, 927–933, doi:10.1038/nsb1196-927. 8901870
[10]
Kurumbail, R.G.; Stevens, A.M.; Gierse, J.K.; McDonald, J.J.; Stegeman, R.A.; Pak, J.Y.; Gildehaus, D.; Miyashiro, J.M.; Penning, T.D.; Seibert, K.; Isakson, P.C.; Stallings, W.C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature？1996, 384, 644–648, doi:10.1038/384644a0. 8967954
[11]
Mitchell, J.A.; Warner, T.D. COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs. Nat. Rev. Drug Discov.？2006, 5, 75–85, doi:10.1038/nrd1929. 16485347
[12]
Zhang, J.J.; Ding, E.L.; Song, Y.Q. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events-meta-analysis of randomized trials. JAMA？2006, 296, 1619–1632, doi:10.1001/jama.296.13.jrv60015. 16968832
[13]
Smith, T.J. Cyclooxygenases as the principle target for the action of NSAIDs. Rheum. Clinics N. Amer.？1998, 24, 501–523, doi:10.1016/S0889-857X(05)70023-5.
[14]
Fourie, A.M. Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase. Curr. Opin. Investig. Drugs？2009, 10, 1173–1182. 19876785
[15]
Charlier, C.; Michaux, C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer nonsteroidal anti-inflammatory drugs. Eur. J. Med. Chem.？2003, 38, 645–659, doi:10.1016/S0223-5234(03)00115-6. 12932896
[16]
Poeckel, D.; Funk, C.D. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc. Res.？2010, 86, 243–253, doi:10.1093/cvr/cvq016. 20093252
Cha, Y.I.; Dubois, R.N. NSAIDs and cancer prevention: targets downstream of COX-2. Annu. Rev. Med.？2007, 58, 239–252, doi:10.1146/annurev.med.57.121304.131253. 17100552
[19]
Palladino, M.A.; Bahjat, F.R.; Theodorakis, E.A.; Moldaver, L.L. Anti-TNF-α therapies: The next generation. Nat. Rev. Drug Disc.？2003, 2, 736–746, doi:10.1038/nrd1175.
[20]
Seruga, B.; Zhang, H.; Bernstein, L.J.; Tannock, I.F. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer？2008, 8, 887–899, doi:10.1038/nrc2507. 18846100
[21]
Craft, J.M.; Watterson, D.M.; Van Eldik, L.J. Neuroinflammation: A potential therapeutic target. Expert Opin. Ther. Targets？2005, 9, 887–900, doi:10.1517/14728222.9.5.887. 16185146
[22]
Muller, N. COX-2 inhibitors as antidepressants and antipsychotics: Clinical evidence. Curr. Opin. Invest. Drugs？2010, 11, 31–42.
[23]
Rainsford, K.D. Anti-inflammatory drugs in the 21st century. Subcell. Biochem.？2007, 42, 3–27. 17612044
[24]
Wallace, J.L.; Ignarro, L.J.; Fiorucci, S. Potential cardioprotective actions of NO-releasing aspirin. Nat. Rev. Drug Discov.？2002, 1, 375–382, doi:10.1038/nrd794. 12120413
[25]
Bernstein, P. Chemistry and structure-activity relationships of leukotriene receptor antagonists. Am. J. Respir. Crit. Care Med.？1998, 157, S220–S226, doi:10.1164/ajrccm.157.6.mar-3. AMBIGUOUS 9647603,9620943
[26]
Ruschitzka, F.T.; Wenger, R.H.; Stallmach, T.; Quaschning, T.; de Wit, C.; Wagner, K.; Labugger, R.; Kelm, M.; Noll, G.; Rülicke, T.; Shaw, S.; Lindberg, R.L.; Rodenwaldt, B.; Lutz, H.; Bauer, C.; Lüscher, T.F.; Gassmann, M. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc. Natl. Acad. Sci. USA？2000, 97, 11609–11613, doi:10.1073/pnas.97.21.11609. 11027359
[27]
Muscara, M.N.; McNight, W.; Del Soldato, P.; Wallace, J.L. Effects of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Pharmacol. Lett.？1998, 62, 235–240.
[28]
Bandarage, U.K.; Chen, L.; Fang, X.; Garvey, D.S.; Glavin, A.; Janero, D.R.; Letts, L.G.; Mercer, G.J.; Saha, J.K.; Schroeder, J.D.; Shumway, M.J.; Tam, S.W. Nitrosothiol esters of diclofenac: Synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J. Med. Chem.？2000, 43, 4005–4016, doi:10.1021/jm000178w. 11052806
[29]
Fitzhugh, A.L.; Keefer, L.K. Diazeniumdiolates: pro- and antioxidant applications of the NONOates. Free Radic. Biol. Med.？2000, 28, 1463–1469, doi:10.1016/S0891-5849(00)00251-3. 10927170
[30]
Velázquez, C.A.; Rao, P.N.P.; Knaus, E.E. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem.？2005, 48, 4061–4067, doi:10.1021/jm050211k.
[31]
Velázquez, C.A.; Chen, Q.H.; Citro, M.L.; Keefer, L.K.; Knaus, E.E. Second-generation aspirin and indomethacin prodrugs possessing an O2-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric oxide donor moiety: Design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem.？2008, 51, 1954–1961. 18314945
[32]
Chegaev, K.; Lazzarato, L.; Tosco, P.; Cena, C.; Marini, E.; Rolando, B.; Carrupt, P.A.; Fruttero, R.; Gasco, A. NO-donor COX-2 inhibitors: New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. J. Med. Chem.？2007, 50, 1449–1457, doi:10.1021/jm0607247. 17335184
Lazzarato, L.; Donnola, M.; Rolando, B.; Marini, E.; Cena, C.; Coruzzi, G.; Guaita, E.; Morini, G.; Fruttero, R.; Gasco, A.; Biondi, S. Searching for new NO-donor aspirin-like molecules: A new class of nitrooxy-acyl derivatives of salicylic acid. J. Med. Chem.？2008, 51, 1894–1903, doi:10.1021/jm701104f. 18293898
[35]
Moriarty, L.M.; Lally, M.N.; Carolan, C.G.; Jones, M.; Clancy, J.M.; Gilmer, J.F. Discovery of a true aspirin prodrug. J. Med. Chem.？2008, 51, 7991–7999, doi:10.1021/jm801094c. 19049433
[36]
Lazzarato, L.; Donnola, M.; Rolando, B.; Chegaev, K.; Marini, E.; Cena, C.; Di Stilo, A.; Fruttero, R.; Biondi, S.; Ongini, E.; Gasco, A. (Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins. J. Med. Chem.？2009, 52, 5058–5068. 20560642
[37]
Rao, P.N.P.; Rajesh, K.G. Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer. IDrugs？2009, 12, 711–722. 19844858
[38]
Biava, M.; Porretta, G.C.; Poce, G.; Supino, S.; Forli, S.; Rovini, M.; Cappelli, A.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Vivoli, E.; Makovec, F.; Anzellotti, P.; Patrignani, P.; Anzini, M. Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-1 selectivity. J. Med. Chem.？2007, 50, 5403–5411. 17915854
[39]
Anzini, M.; Rovini, M.; Cappelli, A.; Vomero, S.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Norcini, M.; Giordani, A.; Makovec, F.; Anzellotti, P.; Patrignani, P.; Biava, M. Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity. J. Med. Chem.？2008, 51, 4476–4481. 18598017
[40]
Biava, M.; Porretta, G.C.; Poce, G.; Battilocchio, C.; Manetti, F.; Botta, M.; Forli, S.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Galeotti, N.; Makovec, F.; Giordani, A.; Anzellotti, P.; Patrignani, P.; Anzini, M. Novel ester and acid derivatives of the 1,5-diarylpyrrole scaffold as anti-inflammatory and analgesic agents: Synthesis and in vitro and in vivo biological evaluation. J. Med. Chem.？2010, 53, 723–733. 19957931
[41]
Gierse, J.; Nickols, M.; Leahy, K.; Warner, J.; Zhang, Y.; Cortes-Burgos, L.; Carter, J.; Seibert, K.; Masferrer, J. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors. Eur. J. Pharmacol.？2008, 588, 93–98, doi:10.1016/j.ejphar.2008.03.057. 18457826
[42]
Renard, J.F.; Arslan, D.; Garbacki, N.; Pirotte, B.; de Leval, X. Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors. J. Med. Chem.？2009, 52, 5864–5871, doi:10.1021/jm900702b. 19791801
Beswick, P.J.; Blackaby, A.P.; Bountra, C.; Brown, T.; Browning, K.; Campbell, I.B.; Corfield, J.; Gleave, R.J.; Guntrip, S.B.; Hall, R.M.; Hindley, S.; Lambeth, P.F.; Lucas, F.; Mathews, N.; Naylor, A.; Player, H.; Price, H.S.; Sidebottom, P.J.; Taylor, N.L.; Webb, G.; Wiseman, J. Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation approach. Bioorg. Med. Chem. Lett.？2009, 19, 4509–4514. 19523822
[45]
Ramalho, T.C.; Rocha, M.V.J.; Da Cunna, E.F.F.; Freitas, M.P. The search for new COX-2 inhibitors: A review of 2002-2008 patents. Expert Opin. Ther. Patents？2009, 19, 1193–1228, doi:10.1517/13543770903059125.
[46]
Reddy, M.V.R.; Billa, V.K.; Pallela, V.R.; Mallireddigari, M.R.; Boominathan, R.; Gabriel, J.L.; Reddy, E.P. Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. Bioorg. Med. Chem.？2008, 16, 3907–3916, doi:10.1016/j.bmc.2008.01.047. 18272371
[47]
Geronikaki, A.A.; Lagunin, A.A.; Hadjipavlou-Litina, D.I.; Eleftheriou, P.T.; Filimonov, D.A.; Poroikov, V.V.; Alam, I.; Saxena, A.K. Computer-aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition. J. Med. Chem.？2008, 51, 1601–1609, doi:10.1021/jm701496h. 18311898
[48]
Dailey, L.A.; Imming, P. 12-Lipoxygenase: Classification, possible therapeutic benefits from inhibition and inhibitors. Curr. Med. Chem.？1999, 6, 389–398. 10101219
[49]
Chowdhury, M.A.; Abdellatif, K.R.; Dong, Y.; Das, D.; Yu, G.; Velázquez, C.A.; Suresh, M.R.; Knaus, E.E. Synthesis and biological evaluation of salicylic acid and N-acetyl-2-carboxybenzenesulfonamide regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. Bioorg. Med. Chem.？2009, 19, 6855–6861, doi:10.1016/j.bmcl.2009.10.083.
[50]
Chowdhury, M.A.; Abdellatif, K.R.; Dong, Y.; Das, D.; Suresh, M.R.; Knaus, E.E. Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: Biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. J. Med. Chem.？2009, 52, 1525–1529, doi:10.1021/jm8015188. 19296694
[51]
Yu, G.; Chowdhury, M.A.; Abdellatif, K.R.; Dong, Y.; Rao, P.N.P.; Das, D.; Velázquez, C.A.; Suresh, M.R.; Knaus, E.E. Phenylacetic acid regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: Evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. Bioorg. Med. Chem.？2010, 20, 896–902, doi:10.1016/j.bmcl.2009.12.073.
[52]
Chen, C.S.; Tan, C.M.; Huang, C.H.; Chang, L.C.; Wang, J.P.; Cheng, F.C.; Chern, J.W. Discovery of 3-(4-bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that also inhibits tumor necrosis factor-alpha production. Bioorg. Med. Chem.？2010, 18, 597–604, doi:10.1016/j.bmc.2009.12.008. 20056549
Blank, M.L.; Lee, T.; Fitzgerald, V.; Snyder, F. A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J. Biol. Chem.？1981, 256, 175–178. 7451433
[55]
Berliner, J.A.; Subbanagounder, G.; Leitinger, N.; Watson, A.D.; Vora, D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc. Med.？2001, 11, 142–147, doi:10.1016/S1050-1738(01)00098-6. 11686004
[56]
Tjoelker, L.W.; Eberhardt, C.; Unger, J.; Trong, H.L.; Zimmerman, G.A.; McIntyre, T.M.; Stafforini, D.M.; Prescott, S.M.; Gray, P.W. Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J. Biol. Chem.？1995, 270, 25481–25487, doi:10.1074/jbc.270.43.25481. 7592717
[57]
Macphee, C.H.; Nelson, J.; Zalewski, A. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr. Opin. Pharmacol.？2006, 6, 154–161, doi:10.1016/j.coph.2005.11.008. 16495153
Tellis, C.C.; Tselepsis, A.D. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim. Biophys. Acta？2009, 1791, 327–338. 19272461
[60]
Caslake, M.J.; Packard, C.J. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat. Rev. Cardiol.？2005, 2, 529–535.
Zalewski, A.; Nelson, J.J.; Hegg, L.; Macphee, C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: Biology, epidemiology, and possible therapeutic target. Arterioscler. Thromb. Vasc. Biol.？2005, 25, 923–931, doi:10.1161/01.ATV.0000160551.21962.a7. 15731492
[63]
Shi, Y.; Zhang, P.; Zhang, L.; Osman, H.; Mohler, E.R.; Macpheec, C.; Zalewski, A.; Postle, A.; Wilensky, R.L. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis？2007, 191, 54–62, doi:10.1016/j.atherosclerosis.2006.05.001. 16765356
[64]
Zalewski, A.; Nelson, J.J.; Heg, J.J.; Macphee, C. Lp-PLA2: A new kid on the block. Clin. Chem.？2006, 52, 1645–1649, doi:10.1373/clinchem.2006.070672. 16873290
[65]
Lee, K.L.; Foley, M.A.; Chen, L.; Behnke, M.L.; Lovering, F.E.; Kirincich, S.J.; Wang, W.; Shim, J.; Tam, S.; Shen, M.W.; Khor, S.; Xu, X.; Goodwin, D.G.; Ramarao, M.K.; Nickerson-Nutter, C.; Donahue, F.; Ku, M.S.; Clark, J.D.; McKew, J.C. Discovery of ecopladib, an indole inhibitor of cytosolic phospholipase A2α. J. Med. Chem.？2007, 50, 1380–1400, doi:10.1021/jm061131z. 17305324
[66]
Suckling, K.E. Phospholipase A2 inhibitors in the treatment of atherosclerosis: A new approach moves forward in the clinic. Expert Opin. Investig. Drugs.？2009, 18, 1425–1430, doi:10.1517/13543780903184583. 19691442
[67]
Rosenson, R.S.; Hislop, C.; McConnell, D.; Elliott, M.; Stasiv, Y.; Wang, N.; Waters, D.D. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): A phase II double-blind, randomized, placebo-controlled trial. Lancet？2009, 373, 649–658, doi:10.1016/S0140-6736(09)60403-7. 19231633
[68]
Corson, M.A. Phospholipase A2 inhibitors in atherosclerosis: The race is on. Lancet？2009, 373, 608–610, doi:10.1016/S0140-6736(09)60378-0. 19231615
[69]
Tew, D.G.; Boyd, H.F.; Ashman, S.; Theobald, C.; Leach, C.A. Mechanism of inhibition of LDL phospholipase A2 by monocyclic beta-lactams: Burst kinetics and the effect of stereochemistry. Biochemistry？1998, 37, 10087–10093, doi:10.1021/bi9801412. 9665713
Leach, C.A.; Smith, S.A. N-Substituted pyridinone and pyrimidinone derivatives for use as Lp-PLA2 inhibitors in the treatment atherosclerosis. World Patent WO 03/086400, 2003.
[72]
Mohler, E.R.; Ballantyne, C.M.; Davidson, M.H.; Hanefeld, M.; Ruilope, L.M.; Johnson, J.L.; Zalewski, A. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: The results of a multicenter, randomized, double-blind, placebo-controlled study. J. Am. Coll. Cardiol.？2008, 51, 1632–1641, doi:10.1016/j.jacc.2007.11.079. 18436114
[73]
Rosenson, R.S. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc. Drugs Ther.？2009, 23, 93–101, doi:10.1007/s10557-008-6148-1. 19153679
[74]
McCullough, P.A. Darapladib and atherosclerotic plaque: Should lipoprotein-associated phospholipase A2 be a therapeutic target? Curr. Atherosclerosis Rep.？2009, 11, 334–337, doi:10.1007/s11883-009-0050-6.
[75]
Jakobsson, P.J.; Morgenstern, R.; Mancini, J.; Ford-Hutchinson, A.; Persson, B. Common structural features of MAPEG—A widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism. Protein Sci.？1999, 8, 689–692, doi:10.1110/ps.8.3.689. 10091672
[76]
Jakobsson, P.J.; Thore′n, S.; Morgenstern, R.; Samuelsson, B. Identification of human prostaglandin E synthase: A microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. USA？1999, 96, 7220–7225, doi:10.1073/pnas.96.13.7220. 10377395
[77]
Samuelsson, B.; Morgenstern, R.; Jakobsson, P.J. Membrane prostaglandin E synthase-1: A novel therapeutic target. Pharmacol. Rev.？2007, 59, 207–224, doi:10.1124/pr.59.3.1. 17878511
[78]
Friesen, R.W.; Mancini, J.A. Microsomal prostaglandin E2 synthase-1 (mPGES-1): A novel anti-inflammatory therapeutic target. J. Med. Chem.？2008, 51, 4059–4067, doi:10.1021/jm800197b. 18459759
[79]
Jegerschoeld, C.; Pawelzik, S.-C.; Purhonen, P.; Bhakat, P.; Gheorghe, K.R.; Gyobu, N.; Mitsuoka, K.; Morgenstern, R.; Jakobsson, P.J.; Hebert, H. Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc. Natl. Acad. Sci. USA？2009, 105, 11110–11115, doi:10.1073/pnas.0802894105.
Koeberle, A.; Zettl, H.; Greiner, C.; Wurglics, M.; Schubert-Zsilavecz, M.; Werz, O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J. Med. Chem.？2008, 51, 8068–8076, doi:10.1021/jm801085s. 19053751
[84]
Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature？1990, 347, 645–650, doi:10.1038/347645a0. 2129546
[85]
Keller, H.; Devchand, P.R.; Perroud, M.; Wahli, W. PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol. Chem.？1997, 378, 651–655, doi:10.1515/bchm.1997.378.7.651. 9278144
[86]
Liedtke, A.J.; Keck, P.R.; Lehmann, F.; Koeberle, A.; Werz, O.; Laufer, S.A. Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). J. Med. Chem.？2009, 52, 4968–4972, doi:10.1021/jm900481c. 19719242
[87]
R？rsch, F.; Wobst, I.; Zettl, H.; Schubert-Zsilavecz, M.; Gr？sch, S.; Geisslinger, G.; Schneider, G.; Proschak, E. Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. J. Med. Chem.？2010, 53, 911–915, doi:10.1021/jm9012505. 20025212
Foxwell, B.; Andreakos, E.; Brennan, F.; Feldmann, M.; Smith, C.; Conron, M. Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents. Ann. Rheum. Dis.？2003, 62, ii90–ii93, doi:10.1136/ard.62.suppl_2.ii90. 14532159
[90]
Wells, J.A.; McClendon, C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature？2007, 450, 1001–1009, doi:10.1038/nature06526. 18075579
[91]
Taylor, P.C. The future of TNF-α antagonism. Future Rheumatol.？2007, 2, 233–236, doi:10.2217/17460816.2.3.233.
